FDA moves to ban bulk compounding of semaglutide

The U.S. Food and Drug Administration (FDA) published a landmark proposal on April 30, 2026, to remove semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. If finalized, this would prohibit outsourcing facilities from compounding these GLP-1 drugs from bulk active pharmaceutical ingredients at industrial scale. The agency cites resolved shortages and alarming new safety data on impurities found in compounded products.

What is the 503B Bulks List and why does it matter?

The 503B Bulks List identifies bulk drug substances that outsourcing facilities may use in compounding when there is a clinical need. As long as a substance is on this list or on the FDA's shortage list, large-scale compounding is legal. Removing semaglutide, tirzepatide, and liraglutide would close this legal pathway. The public comment period ends June 30, 2026, after which the FDA will make a final decision. Learn more about semaglutide and its clinical evidence.

What safety risks were found?

The FDA's proposal is backed by a comprehensive three-year investigation by Novo Nordisk analyzing compounded samples. The findings are concerning:

• Formaldehyde adducts: Two injectable compounded semaglutide products contained dangerous levels of formaldehyde adducts - 95.12% and 70.35%. Formaldehyde is a known carcinogen.
• High molecular weight proteins (HMWPs): Three products showed HMWP levels up to 2.69%, posing immunogenicity risks.
• Unknown impurities: Multiple samples contained dimers, trimers, and truncated peptide fragments.
• Undisclosed active ingredients: One product contained 29% undisclosed tirzepatide in addition to the stated semaglutide.

The FDA emphasizes that these products lack the safety, efficacy, and quality assurances of FDA-approved drugs. Learn more about tirzepatide and its regulatory status.

What does this mean for consumers?

Patients who relied on cheaper compounded versions of Ozempic, Wegovy, Mounjaro, or Zepbound may face reduced access. However, the FDA notes that branded FDA-approved products are now widely available again. The agency strongly warns against purchasing GLP-1 products labeled "for research purposes only" or "not for human consumption" - a common loophole used by peptide vendors. These products are of unknown quality and may be harmful.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider for questions about your medication.